Pesquisar
Xencor Inc
XNCRAdicionar à lista de desejos
20.210USD
-1.280-5.96%
Fechamento 07-31 16:00（ET）Cotações atrasadas em 15 min
1.50BValor de mercado
PerdaP/L TTM
Mais detalhes de Xencor Inc Empresa
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases. It has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
Informações de Xencor Inc
Código da empresaXNCR
Nome da EmpresaXencor Inc
Data de listagemDec 03, 2013
CEODahiyat (Bassil I)
Número de funcionários250
Tipo de títulosOrdinary Share
Fim do ano fiscalDec 03
Endereço465 N. Halstead St.
CidadePASADENA
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal91107
Telefone16263055900
Sitehttps://xencor.com/
Código da empresaXNCR
Data de listagemDec 03, 2013
CEODahiyat (Bassil I)
Executivos da empresa Xencor Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. John R. Desjarlais, Ph.D.
Dr. John R. Desjarlais, Ph.D.
Executive Vice President - Research, Chief Scientific Officer
Executive Vice President - Research, Chief Scientific Officer
231.70K
+6.74%
Ms. Celia E. Eckert
Ms. Celia E. Eckert
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
57.51K
+21.17%
Mr. Bart Jan Cornelissen
Mr. Bart Jan Cornelissen
Senior Vice President, Chief Financial Officer
Senior Vice President, Chief Financial Officer
48.35K
-7.24%
Mr. Kurt A. Gustafson
Mr. Kurt A. Gustafson
Independent Director
Independent Director
11.32K
+42.63%
Mr. Richard J. (Rich) Ranieri
Mr. Richard J. (Rich) Ranieri
Independent Director
Independent Director
10.32K
+46.76%
Mr. Todd E. Simpson
Mr. Todd E. Simpson
Independent Director
Independent Director
10.30K
--
Dr. Bassil I. Dahiyat, Ph.D.
Dr. Bassil I. Dahiyat, Ph.D.
President, Chief Executive Officer, Founder and Director
President, Chief Executive Officer, Founder and Director
--
--
Dr. A. Bruce Montgomery, M.D.
Dr. A. Bruce Montgomery, M.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. Kevin C. Gorman, Ph.D.
Dr. Kevin C. Gorman, Ph.D.
Independent Director
Independent Director
--
--
Dr. Ellen Gwen Feigal, M.D.
Dr. Ellen Gwen Feigal, M.D.
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. John R. Desjarlais, Ph.D.
Dr. John R. Desjarlais, Ph.D.
Executive Vice President - Research, Chief Scientific Officer
Executive Vice President - Research, Chief Scientific Officer
231.70K
+6.74%
Ms. Celia E. Eckert
Ms. Celia E. Eckert
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
57.51K
+21.17%
Mr. Bart Jan Cornelissen
Mr. Bart Jan Cornelissen
Senior Vice President, Chief Financial Officer
Senior Vice President, Chief Financial Officer
48.35K
-7.24%
Mr. Kurt A. Gustafson
Mr. Kurt A. Gustafson
Independent Director
Independent Director
11.32K
+42.63%
Mr. Richard J. (Rich) Ranieri
Mr. Richard J. (Rich) Ranieri
Independent Director
Independent Director
10.32K
+46.76%
Mr. Todd E. Simpson
Mr. Todd E. Simpson
Independent Director
Independent Director
10.30K
--
Perguntas frequentes
Quem são os cinco principais acionistas de Xencor Inc?
Os cinco principais acionistas de Xencor Inc são: Dr. John R. Desjarlais, Ph.D.
Qual é a maior fonte de receita da Xencor Inc?
Em 2026Q4, o segmento de negócios Royalties gerou a maior receita para Xencor Inc, totalizando 80.28M e representando 63.93% da receita total.